Hanmi Pharmaceutical challenges invalidity of patent for Ezetrol… A war for exclusive rights has begun

Hanmi Pharmaceutical will challenge nullity of patent for compositions of Merck’s Ezetrol(Ezetimibe), medication for hyperlipidemia.

People’s attention has been drawn to whether the challenge for the nullity would effect on preferred sales product authority followed by the patent linkage system next March as many pharmaceutical companies, including Hanmi Pharmaceutical, are developing complexe...